Intensity Therapeutics Inc (NASDAQ: INTS)’s stock price has plunge by -3.96%relation to previous closing price of $0.3. Nevertheless, the company has seen a -11.44% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-30 that SHELTON, Conn., June 30, 2025 /PRNewswire/ — Intensity Therapeutics, Inc. (Nasdaq: INTS) (“Intensity” or “the Company”), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that INT230-6 achieved complete responses in a murine models of Malignant Peripheral Nerve Sheath Tumor (“MPNST”).
Is It Worth Investing in Intensity Therapeutics Inc (NASDAQ: INTS) Right Now?
Company’s 36-month beta value is 3.80.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy”, 2 as “overweight”, 2 as “hold”, and 0 as “sell”.
The public float for INTS is 14.05M, and currently, short sellers hold a 4.69% ratio of that floaft. The average trading volume of INTS on July 08, 2025 was 1.31M shares.
INTS’s Market Performance
INTS stock saw a decrease of -11.44% in the past week, with a monthly decline of -39.96% and a quarterly a decrease of -85.54%. The volatility ratio for the week is 11.86%, and the volatility levels for the last 30 days are 16.78% for Intensity Therapeutics Inc (INTS). The simple moving average for the past 20 days is -17.43% for INTS’s stock, with a -86.19% simple moving average for the past 200 days.
INTS Trading at -35.38% from the 50-Day Moving Average
After a stumble in the market that brought INTS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.44% of loss for the given period.
Volatility was left at 16.78%, however, over the last 30 days, the volatility rate increased by 11.86%, as shares sank -36.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -78.20% lower at present.
During the last 5 trading sessions, INTS fell by -11.44%, which changed the moving average for the period of 200-days by -93.04% in comparison to the 20-day moving average, which settled at $0.3432. In addition, Intensity Therapeutics Inc saw -94.18% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of Intensity Therapeutics Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for INTS
The total capital return value is set at -34.94%. Equity return is now at value -298.57%, with -194.04% for asset returns.
Based on Intensity Therapeutics Inc (INTS), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at -98.04.
Currently, EBITDA for the company is -16.24 million with net debt to EBITDA at 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.63.
Conclusion
In a nutshell, Intensity Therapeutics Inc (INTS) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
